Bioversija - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 436,287 | 442,741 | 372,844 | 793,116 | 1,400,787 | 1,538,064 | 1,802,869 | 1,684,241 |
| Profit before tax | 134,126 | 123,253 | 90,801 | 426,361 | 619,020 | 345,210 | 493,556 | 245,451 |
| Net profit | 113,673 | 103,956 | 81,437 | 390,471 | 522,335 | 289,643 | 413,641 | 199,340 |
| Equity | 105,522 | 209,478 | 290,915 | 681,387 | 1,203,722 | 1,443,365 | 1,827,006 | 1,976,346 |
| Liabilities | 219,901 | 25,121 | 15,391 | 318,665 | 246,855 | 159,815 | 475,390 | 470,077 |
| Non-current assets | 137,315 | 117,177 | 20,728 | 341,306 | 517,585 | 398,856 | 961,281 | 867,308 |
| Current assets | 187,918 | 117,422 | 284,609 | 658,470 | 929,573 | 1,199,034 | 1,331,944 | 1,576,635 |
| Total assets | 325,233 | 234,599 | 305,337 | 999,776 | 1,447,158 | 1,597,890 | 2,293,225 | 2,443,943 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 469,719 | 391,886 | 408,339 |
| Social insurance contributions | - | - | - | - | - | 103,184 | 138,453 | 176,899 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +32.3% | +1.5% | -15.8% | +112.7% | +76.6% | +9.8% | +17.2% | -6.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 35.0% | 44.3% | 26.7% | 39.1% | 36.1% | 18.1% | 18.0% | 8.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 107.7% | 49.6% | 28.0% | 57.3% | 43.4% | 20.1% | 22.6% | 10.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 26.1% | 23.5% | 21.8% | 49.2% | 37.3% | 18.8% | 22.9% | 11.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 30.7% | 27.8% | 24.4% | 53.8% | 44.2% | 22.4% | 27.4% | 14.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.1 | 0.1 | 0.1 | 0.5 | 0.2 | 0.1 | 0.3 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 48,929 | 62,505 | 114,721 | 264,372 | 224,126 | 119,849 | 125,782 | 98,590 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Bioversija - Social security debts
The company had no debts to Sodra
Bioversija - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Bioversija, UAB (code 302290605) is a private limited liability company engaged in research and experimental development on other natural sciences and engineering. In 2025, the company generated revenue of €1.68M and net profit of €199.3K, with a profit margin of 11.8%. Revenue declined by 6.6% year on year from €1.80M in 2024, while profitability also softened from €413.6K net profit in 2024 and €289.6K in 2023. Over the three-year period, revenue rose from €1.54M in 2023 to a peak in 2024 before easing in 2025, whereas net profit followed the same pattern and remained positive throughout. The balance sheet strengthened in 2025, with total assets of €2.44M, equity of €1.98M and liabilities of €470.1K. The equity ratio stood at 80.9% and debt to equity at 0.24, indicating a conservative capital structure. Return on equity was 10.1% and return on assets 8.2%. Asset turnover was 0.69x. With revenue per employee of €99.1K and profit per employee of €11.7K, the company showed solid productivity in 2025.